• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

    12/5/23 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email

    BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition.

    "OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing them with the information needed to guide conversations about symptoms and management strategies," said Megan Filoramo, RN, MSN, APN-C. "I'm excited to be a part of this awareness initiative and help shed light on this underdiagnosed patient population."

    The first annual OIC Awareness Day will provide a platform for patients, caregivers, and HCPs to discuss this condition and encourage them to join the #OICAwarenessDay movement.

    "As an organization committed to helping individuals living with chronic pain, we understand the challenges individuals living with OIC experience," said Nicole Hemmenway, CEO of the U.S. Pain Foundation. "We are passionate about awareness and education that empowers those impacted by OIC to feel comfortable having a conversation with their HCP."

    More than 20 percent of American adults experience chronic pain and utilize prescribed medications, such as opioids, to help manage their conditions. These opioids can cause debilitating side effects including OIC, a specific type of constipation, and one of the most common side effects of opioid use.

    "For over three decades, IFFGD has championed the need for research to enhance the management options available for patients with gastrointestinal (GI) disorders such as OIC," said Ceciel Rooker, President and Executive Director of IFFGD. "The symptoms, burdens, and challenges that many face while living with OIC can be debilitating, and their voices must be heard."

    The first annual OIC Awareness Day will kick off with a proclamation in Bridgewater, NJ - the town where Salix is headquartered. Dec. 5 is now also officially recognized as OIC Awareness Day in the National Day Archives. A new website, OICAwarenessDay.com, was created to provide information and resources to HCPs, patients, and caregivers about the causes, symptoms, and management of OIC. Salix also partnered with influencers to share online about the movement using the hashtag #vOICesOfOIC.

    For more information on OIC and to learn how you can join the #OICAwarenessDay movement, please visit www.OICAwarenessDay.com

    About Salix

    Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter (X) and LinkedIn.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter (X) and LinkedIn.

    About U.S. Pain Foundation

    The U.S. Pain Foundation is a 501(c)(3) nonprofit with a mission to empower, educate, connect, and advocate for individuals living with chronic illnesses and serious injuries that cause pain, as well as their care partners and clinicians. Through its multiple programs and services, the organization works to elevate the patient voice, increase disease-state education, improve pain care through policy change, expand outreach to underserved and marginalized communities, and provide comprehensive resources to ensure individuals are supported and empowered along their journeys. Learn more at uspainfoundation.org.

    About The International Foundation for Gastrointestinal Disorders

    The International Foundation for Gastrointestinal Disorders (IFFGD) is a nonprofit education and research organization dedicated to improving the lives of people affected by chronic gastrointestinal illnesses. Founded in 1991, IFFGD helps improve patient outcomes by enhancing awareness, improving education, and supporting and encouraging research into treatments and cures for chronic digestive disorders.

    Media Contacts:

    Gianna Scalera
    salixcommunications@salix.com
    (908) 541-2110

    Kevin Wiggins
    corporate.communications@bauschhealth.com
    (908) 541-3785

    SOURCE: Salix Pharmaceuticals



    View source version on accesswire.com:
    https://www.accesswire.com/812898/salix-in-collaboration-with-the-us-pain-foundation-and-the-international-foundation-for-gastrointestinal-disorders-establish-the-inaugural-opioid-induced-constipation-oic-awareness-day

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    12/9/2025$8.00Equal Weight
    Barclays
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

    Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes

    5/28/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

    LAVAL, QC, May 13, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.DetailsDate:        Wednesday, May 20, 2026Time:        9:30 a.m. U.S. ETWebcast:  http://ir.bauschhealth.com/events-and-presentationsA replay of the event will be available on the investor relations website following t

    5/13/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    SEC Filings

    View All

    SEC Form SD filed by Bausch Health Companies Inc.

    SD - Bausch Health Companies Inc. (0000885590) (Filer)

    6/1/26 4:06:14 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    5/19/26 4:18:10 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    4/29/26 4:10:14 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wechsler Amy B was granted 45,871 shares, increasing direct ownership by 17% to 313,585 units (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    5/26/26 7:05:06 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Roberts Eiry was granted 45,871 shares (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    5/26/26 7:02:25 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Power Robert N was granted 45,871 shares, increasing direct ownership by 18% to 300,594 units (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    5/26/26 7:00:09 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Bausch Health with a new price target

    Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

    7/10/24 8:35:33 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Welcomes Two New Members to the Executive Leadership Team

    LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

    7/19/24 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Financials

    Live finance-specific insights

    View All

    BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

    First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q

    4/29/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

    SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

    8/19/24 5:48:41 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

    SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

    2/13/24 4:30:26 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care